Case TS-B94381A514 Sept 2026Health

A bizarre medical case showed that Diet Coke can have a very unusual use in medicine. A woman taking a GLP-1 medication developed a gastric bezoar, a hardened mass of undigested food in the stomach. Doctors treated her with 1.5 litres of Diet Coke over two days, and follow-up examination showed that the mass had dissolved." (Intake…

Plain restatementIn a reported clinical case, a patient using a GLP-1 receptor agonist developed a gastric bezoar, was given diet cola as dissolution therapy, and a follow-up endoscopy found the bezoar no longer present.

Mostly accurateConfidence Medium
What this verdict means →

This one is largely accurate. A real medical case, reported by Live Science and NewsNation in July 2026, describes a 36-year-old Massachusetts woman on a GLP-1 weight loss drug who developed a gastric bezoar, a hardened mass of undigested food. She drank roughly 1.5 liters of Diet Coke, and a follow-up endoscopy found the mass had dissolved. Using cola to dissolve these masses is a recognized medical technique, supported by a published systematic review that found it fully dissolves such masses in about half of cases. Two details in the viral version are off: the cola was a single scaled-down dose, not 1.5 liters a day, and doctors also stopped her GLP-1 medication and gave her another prescription, so soda was not the only treatment. This is also a single patient case, and the doctors themselves wrote that they do not understand why cola works. The before-and-after images in the post could not be verified as coming from this case, and the original journal publication was not directly located.

The drift / as claimed vs as evidenced

A [drifted from the evidence:] bizarre medical case [drifted from the evidence:] showed that Diet Coke can have a [drifted from the evidence:] very unusual use in medicine. A woman taking a GLP-1 [drifted from the evidence:] medication developed a gastric bezoar, [drifted from the evidence:] a hardened mass of undigested food in the stomach. Doctors treated her with 1.5 litres of Diet [drifted from the evidence:] Coke over two days, and follow-up examination showed that the mass had dissolved." (Intake summary rendered it as [drifted from the evidence:] "1.5 liters of Diet Coke a [drifted from the evidence:] day, with the [drifted from the evidence:] mass gone within two days." Post images read: BEFORE / AFTER 2 DAYS.)


[added by the neutral restatement:] In a [added by the neutral restatement:] reported clinical case, a [added by the neutral restatement:] patient using a GLP-1 [added by the neutral restatement:] receptor agonist developed a gastric bezoar, [added by the neutral restatement:] was given diet [added by the neutral restatement:] cola as [added by the neutral restatement:] dissolution therapy, and a [added by the neutral restatement:] follow-up endoscopy found the [added by the neutral restatement:] bezoar no longer present.

Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.

The trace / claim to source

Where it appeared
Submitted image
Omitted qualifier
A load-bearing condition from the source quietly disappears from the claim.
Exaggeration
A real finding gets inflated: stronger, bigger, faster, or more certain than the evidence supports.
Tertiary sourcemainstream broadcast outlet
NewsNation, "Doctors use Diet Coke to dissolve woman's rare stomach mass likely caused by of GLP-1 drug," 21 July 2026
Source
NOT FOUND: the original published case report (journal, authors, DOI). Search quota exhausted before it could be located.
Secondary sourcequality science journalism
Live Science, "Diagnostic dilemma: Huge mass in woman's stomach was likely caused by Ozempic-style drug and dissolved with diet soda," July 2026
Primary sourcepeer-reviewed journal
Ladas et al., "Systematic review: Coca-Cola can effectively dissolve gastric phytobezoars as a first-line treatment," Alimentary Pharmacology & Therapeutics (2013)
Primary sourcepeer-reviewed case report
Keng et al., "A Case Report of Bezoar-Induced Small Bowel Obstruction: A Potential Surgical Complication of Semaglutide," Cureus, Dec 2025
Primary sourcepeer-reviewed
Coca-Cola dissolution therapy for duodenal bezoar, case report, PubMed 2026
● Primary source found
What is true
  • A real, media-documented clinical case exists, published as a case report and covered by Live Science and NewsNation in July 2026.
  • The patient was taking a GLP-1 receptor agonist and developed a gastric bezoar.
  • Diet Coke was the dissolution agent used, in an approximate volume of 1.5 liters.
  • A follow-up endoscopy found the bezoar had dissolved.
  • The approximate two-day timeframe is consistent with reporting: symptom relief the day after ingestion, with dissolution confirmed on follow-up endoscopy.
  • The post's closing qualifier, that cola has been used in medically supervised bezoar treatments, is accurate and supported by a published systematic review.
  • The MLA citation points to a real NewsNation article, though the date is off by about one day from the publication date indexed.
What is misleading
  • Dose and duration framing (omitted qualifier): the intake wording "1.5 liters a day" and the post's "over two days" both misdescribe the regimen. Reporting indicates a single scaled-down administration of about 1.5 liters, which was roughly half the standard 3-liters-in-12-hours protocol. This detail matters because it is the opposite of a daily maintenance regimen.
  • Treatment was not cola alone (omitted qualifier): secondary coverage indicates doctors also took the patient off the GLP-1 medication and gave her a prescription. Presenting Diet Coke as the sole curative intervention overstates its isolated role.
  • Single case presented as a general property (temporal and scope overreach): "Diet Coke can have a very unusual use in medicine" is loose but defensible given the systematic review; however, the before/after visual format implies reproducible, predictable efficacy that a single case cannot demonstrate. Even the systematic review found complete dissolution with cola alone in only about half of cases.
  • Mechanism implied but unknown: the framing suggests Diet Coke reliably "dissolves" masses, while the treating clinicians stated the mechanism is not understood.
  • Causal attribution to the GLP-1 drug is a clinical inference, not an established cause. Headlines used "likely caused" and the post drops that hedge.
  • Brand framing: the on-image text "Diet Coke - NO SUGAR NO CALORIES" reads as product marketing attached to a medical case. Diet cola was chosen here because the patient had diabetes, not because sugar-free formulations are therapeutically superior.
What is uncertain
  • The original published case report (journal, authors, DOI, exact wording of the imaging and endoscopy findings) was not retrieved. Search quota was exhausted after the sources listed above.
  • Whether the "BEFORE" and "AFTER 2 DAYS" images in the post are the actual endoscopic or imaging images from this case, or unrelated stock or borrowed images. This could not be verified.
  • The exact interval between cola administration and the confirmatory follow-up endoscopy.
  • The bezoar's composition, its precise measured size, and whether any residual material remained.
  • What additional prescription the patient received and what role it played.
  • Whether the MLA date of 22 July 2026 reflects an update, a syndication, or a transcription error.
Evidence summary

The underlying case is real and was covered by both Live Science and NewsNation. NewsNation reported that a soda played an unexpected role in treating a rare abdominal blockage in a Massachusetts woman, a 36-year-old patient who went to the emergency room after about a month of nausea, vomiting and decreased appetite. She drank about 1.5 liters of Diet Coke, roughly half the amount typically recommended for treating a bezoar, because she did not like the carbonation; the next day she reported a "tugging" sensation in her abdomen followed by relief from nausea and discomfort, and a follow-up endoscopy showed the bezoar had dissolved. The same outlet reported the mass was not blocking the opening to her small intestine but was taking up significant space and making it harder for food to move through her digestive system, and that physicians believe the bezoar formed due to delayed gastric emptying, a known effect of GLP-1 medications such as semaglutide. The treating clinicians' own framing was cautious. Live Science quoted the case report as stating that "Existing evidence, largely from case series and anecdotal experiences, supports the administration of 3 liters [0.8 gallons] of cola, either orally or through a nasogastric tube, within a 12-hour window." The report also stated that "It is not well understood whether acidity, carbonation, or another mechanism accounts for dissolution of the bezoar." The general technique is established in the literature, not a novelty. A systematic review found that in 91.3% of cases phytobezoar resolution with Coca-Cola administration was successful, either as a single treatment (50%) or combined with further endoscopic techniques, with only 4 patients requiring surgery. Its authors concluded that Coca-Cola completely dissolves gastric phytobezoars in about half of cases and facilitates complete dissolution by subsequent endoscopic techniques in the majority of patients. The GLP-1 to bezoar link also has independent support. A 2025 Cureus case report described acute small bowel obstruction due to a bezoar in a 65-year-old woman on semaglutide for weight loss, with the authors postulating that semaglutide-induced gastroparesis and slow intestinal transit may have contributed to bezoar formation.

Complete reasoning
The core of this claim checks out against multiple independent sources: a real case report, covered by Live Science and then NewsNation, describing a GLP-1-associated gastric bezoar in a 36-year-old woman that dissolved after about 1.5 liters of Diet Coke, confirmed by follow-up endoscopy. The technique is not fringe; a peer-reviewed systematic review supports cola dissolution as a first-line phytobezoar therapy, and the GLP-1 to bezoar association appears in separate published case reports. The distortions are real but secondary: the dose is misdescribed as daily or spread over two days when it was a single scaled-down administration, the post omits that the GLP-1 drug was stopped and other medication prescribed, and a single case is presented in a before-and-after format that implies more reliability than n = 1 supports. Confidence is Medium rather than High because the original case report was not directly retrieved and the post's images could not be authenticated.
Use this case

The reply receipt is formatted for pasting into the thread where the claim is circulating.

Compact share page: verify.trueseeker.com/s/b94381a52050/hQsgx2q0T_QTH0wtAYCt2gc

Ask this case

Answers come only from the case file above; nothing is added.

Did Diet Coke really dissolve a woman's stomach mass?

Yes. A 36-year-old woman on a GLP-1 medication developed a gastric bezoar, a hardened mass of undigested food, and after drinking about 1.5 liters of Diet Coke a follow-up endoscopy found the mass had dissolved.

Did she drink 1.5 liters of Diet Coke every day for two days?

No. Reporting indicates it was a single administration of about 1.5 liters, roughly half the standard protocol of 3 liters within 12 hours, not a daily amount over two days.

Was Diet Coke the only treatment she received?

No. Doctors also stopped her GLP-1 medication and gave her another prescription, so the soda was not the sole intervention.

Do doctors know why cola dissolves these masses?

No. The case report itself states it is not well understood whether acidity, carbonation, or another mechanism is responsible.

Is this a proven, general medical technique or just one unusual case?

The technique is established in the literature, a systematic review found cola fully dissolves this type of mass in about half of cases, but this particular report is a single patient case, so it cannot show the treatment is reliably reproducible.

Similar cases on record

Mostly accurate: In a reported clinical case, a patient using a GLP-1 receptor agonist developed a gastric … | TrueSeeker